Overview
Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)
Status:
Terminated
Terminated
Trial end date:
2011-05-01
2011-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To determine whether dasatinib plus lomustine are effective for treatment of recurrent glioblastomaPhase:
Phase 1/Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Bristol-Myers SquibbCollaborator:
European Organisation for Research and Treatment of Cancer - EORTCTreatments:
Dasatinib
Lomustine
Criteria
Inclusion Criteria:- Patients with histological or cytological proven glioblastoma multiforme
- Recurrent or progressive disease documented by magnetic resonance imaging (MRI)
- World Health Organization (WHO) Performance status 0 - 2
- Patient may have been operated for recurrence
- For non operated patients, recurrent disease must be at least one bidimensionally
measurable target lesion with one diameter of at least 2cm
- Patients must be on a stable or decreasing dose of corticosteroids for at least 1 week
prior to baseline MRI
Exclusion Criteria:
- Patients with histological or cytological proven glioblastoma multiforme
- Completion of radiotherapy to the brain less than 3 months prior to
registration/randomization
- Prior treatment with high dose radiotherapy, stereotactic radiosurgery or internal
radiation therapy
- Previous or current malignancy at other sites within prior 3 years